Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1232 - Prognostic significance of circulating microRNA-155 expression in breast cancer patients (36P)

Date

18 Nov 2017

Session

Poster lunch

Presenters

Prasant Yadav

Citation

Annals of Oncology (2017) 28 (suppl_10): x7-x15. 10.1093/annonc/mdx653

Authors

P. Yadav1, M. Mirza1, K. Nandi1, S.K. Jain2, R. Kaza2, N. Khurana3, A. Saxena1

Author affiliations

  • 1 Deptt. Of Biochemistry, Maulana Azad Medical College & Associated Hospitals, 110002 - New Delhi/IN
  • 2 Deptt. Of Surgery, Maulana Azad Medical College & Associated Hospitals, 110002 - New Delhi/IN
  • 3 Deptt. Of Pathology, Maulana Azad Medical College & Associated Hospitals, 110002 - New Delhi/IN
More

Resources

Abstract 1232

Background

Breast cancer (BC) is the leading cause of cancer‐related mortality in the female population. MicroRNA‐155 (miR‐155), an oncogenic non‐coding RNA, plays an important role in the pathogenesis of breast cancer. However, the level of circulating miR-155 expression and its clinical significance are not well established. The aim of present study was to evaluate the prognostic role of circulating miR-155 expression in serum of breast cancer patients.

Methods

Study includes 75 serum samples from histopathologically confirmed, newly diagnosed cases of breast cancer and 75 healthy control subjects. Total RNA from serum was isolated by using Trizol reagent, polyadenylated and reverse transcribed into cDNA. The expression level of miR‐155 was detected by using qRT‐PCR. Relative expression was determined with matched controls using U6 snRNA as a reference. Levels of miRNA expression were compared with distinct clinicopathological features. The total follow-up period was 41 months and mean follow-up time was 28 months. Kaplan-Meier survival analysis was performed for overall survival of breast cancer patients. The study was ethically approved by Institutional Ethics Committee, Maulana Azad Medical College, New Delhi.

Results

The overall relative fold increase of miR‐155 expression in breast cancer patients was 8.80 fold compared to the healthy controls. When the level of miR‐155 expression was compared with distinct clinicopathological features, there was a significant association seen between miR‐155 expression with TNM stage (p = 

Conclusions

Our findings suggest that overexpression of serum miR‐155 expression might be a useful, non-invasive, prognostic biomarker for breast cancer patients. A large pool study will be necessary to confirm our findings.

Clinical trial identification

Legal entity responsible for the study

Prof. Dr. Alpana Saxena

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings